drugset / Trial / NCT04659096
A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION537 when administered by intravenous infusion in patients with advanced solid tumors.
Timeline
- Start
- 2021-01-05
- Primary completion
- 2022-10-19
- Completion
- 2022-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ION537 | Unknown | — | Intravenous |